UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Higher dose and dose-rate in smaller tumors result in improved tumor control

Mayer, A; Tsiompanou, E; Flynn, AA; Pedley, RB; Dearling, J; Boden, R; Begent, RHJ; (2003) Higher dose and dose-rate in smaller tumors result in improved tumor control. CANCER INVEST , 21 (3) 382 - 388. 10.1081/CNV-120018229.

Full text not available from this repository.

Abstract

Small tumors are more sensitive to radioimmunotherapy (RIT) than larger ones. A greater proportion of viable radiosensitive areas in small tumors, higher antibody uptake, and radiation dose may be responsible. Six groups of mice with small (median tumor size 0.06 cm(3)) or large LoVo xenografts (median tumor size 0.38 cm(3)) received either RIT using a I-131-labeled anti-CEA antibody A5B7, 5-fluorouracil (5-FU) modulated with folinic acid (FA), or no treatment. The % injected activity/gram, antibody distribution in viable and necrotic areas, and dose distribution were determined. High-power microscopy images of the original section were reconstructed to estimate the proportion of viable areas. Mice with small and large tumors grew significantly less rapidly when treated with RIT compared to the control group (p < 0.0004 and p < 0.003, respectively), while 5-FU was ineffective. Small tumors treated with RIT grew less than large tumors (p < 0.02). A higher amount of % injected activity/gram of tumor (median 26.6% vs. 8.1%, p = 0.0007) and a higher dose-rate were found in small tumors at 24 hours post injection (viable areas: 56.2 +/- 23.7 vs. 13.3 +/- 7 cGy/h, necrosis 19.2 +/- 16.3 vs. 4.9 +/- 4.7 cGy/h, p = 0.0007). It appears that as viable tumor masses grow the access to them decreases and this has a fourfold effect on dose delivered for RIT in this example. These data support the consideration of use of RIT for adjuvant treatment in colon cancer.

Type: Article
Title: Higher dose and dose-rate in smaller tumors result in improved tumor control
DOI: 10.1081/CNV-120018229
Keywords: LoVo xenografts, radioimmunotherapy, radioluminography, dose-rate, MONOCLONAL-ANTIBODY, COLORECTAL-CANCER, SOLID TUMORS, RADIOIMMUNOTHERAPY, THERAPY, MACROMOLECULES, CHEMOTHERAPY, XENOGRAFT, TRIAL, CEA
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: http://discovery.ucl.ac.uk/id/eprint/155408
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item